Abstract
Studies of amyloid precursor protein transgenic mice suggest that immune responses to amyloid β peptide (Aβ) may be instrumental in the removal of plaques from the brain, but the initial clinical trial of an Aβ vaccine in patients with Alzheimer’s disease (AD) was halted as the result of serious neurological complications in some patients. We now provide evidence that AD patients exhibit an enhanced immune response to Aβ and that, contrary to expectations, Aβ antibodies enhance the neurotoxic activity of the peptide. Serum titers to Aβ were significantly elevated in AD patients and Aβ antibodies were found in association with amyloid plaques in their brains, but there was no evidence of cell-mediated immune responses to Aβ in the patients. Aβ antibodies were detected in the serum of old APP mutant transgenic mice with plaque-like Aβ deposits, but not in the serum of younger transgenic or nontransgenic mice. Serum from APP mutant mice potentiated the neurotoxicity of Aβ. Our data suggest that a humoral immune response to Aβ in AD patients may promote neuronal degeneration, a process with important implications for the future of vaccine-based therapies for AD.
Article PDF
Similar content being viewed by others
References
Bard F., Cannon C., Barbour R., et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–919.
Birmingham K. and Frantz S. (2002) Set back to Alzheimer vaccine studies. Nat. Med. 8, 199, 200.
Borchelt D. R., Thinakaran G., Eckman C. B., et al. (1996) Familial Alzheimer’s disease linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron 17, 1005–1013.
Cai X. D., Golde T. E., and Younkin S. G. (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514–516.
Cairns N. J., Chadwick A., Lantos P. L., et al. (1993) Beta A4 protein deposition in familial Alzheimer’s disease with the mutation in codon 717 of the beta A4 amyloid precursor protein gene and sporadic Alzheimer’s disease. Neurosci. Lett. 149, 137–140.
Citron M., Oltersdorf T., Haass C., et al. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature 360, 672–674.
Cheng B. and Mattson M. P. (1992) Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: Prevention by NGF and bFGF. Exp. Neurol. 117, 114–123.
DeMattos R. B., Bales K. R., Cummins D. J., et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855.
Du Y., Dodel R., Hampel H., et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57, 801–805.
Esler W. P. and Wolfe M. S. (2001) A portrait of Alzheimer secretases—new features and familiar faces. Science 293, 1449–1454.
Estus S., Tucker H. M., van Rooyen C., et al. (1997) Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant “apoptotic” pattern of gene induction. J. Neurosci. 17, 7736–7745.
Frenkel D., Katz O., and Solomon B. (2000) Immunization against Alzheimer’s beta-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA 97, 11,455–11,459.
Games D., Bard F., Grajeda H., et al. (2000) Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1–42. Ann. NY Acad. Sci. 920, 274–284.
Gotz J., Chen F., van Dorpe J., and Nitsch R. M. (2001) Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491–1495.
Guo Q., Sebastian L., Sopher B. L., et al. (1999) Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J. Neurochem. 72, 1019–1029.
Hyman B. T., Smith C., Buldyrev I., et al. (2001) Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann. Neurol. 49, 808–810.
Iwatsubo T., Odaka A., Suzuki N., et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific Abeta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45–53.
Janus C., Pearson J., McLaurin J., et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408, 979–982.
LeVine H., 3rd. (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309, 274–284.
Lewis J., Dickson D. W., Lin W. L., et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487–1491.
Markesbery W. R. (1997) Neuropathological criteria for the diagnosis of Alzheimer’s disease. Neurobiol. Aging 18, S13-S19.
Mattson M. P. (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081–1132.
Mattson M. P., Fu W., Waeg G., et al. (1997) 4-hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. NeuroReport 8, 2275–2281.
Morgan D., Diamond D. M., Gottschall P. E., et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408, 982–985.
Nath A. and Wolinsky J. S. (1990) Antibody response to rubella virus structural proteins in multiple sclerosis. Ann. Neurol. 27, 533–536.
Pike C. J., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311–314.
Selkoe D. J. (2000) Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. NY Acad. Sci. 924, 17–25.
Schenk D., Barbour R., Dunn W., et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177.
Scheuner D., Eckman C., Jensen M., et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–870.
Simmons L. K., May P. C., Tomaselli K. J., et al. (1994) Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 45, 373–379.
Suzuki N., Cheung T. T., Cai X. D., et al. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336–1340.
Tamaoka A., Kondo T., Odaka A., et al. (1994) Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer’s disease. Biochem. Biophys. Res. Commun. 205, 834–842.
Varadarajan S., Yatin S., Aksenova M., and Butterfield D. A. (2000) Review: Alzheimer’s amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184–208.
Weksler M. E., Relkin N., Turkenich R., et al. (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37, 943–948.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nath, A., Hall, E., Tuzova, M. et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity. Neuromol Med 3, 29–39 (2003). https://doi.org/10.1385/NMM:3:1:29
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/NMM:3:1:29